Zymeworks (NASDAQ:ZYME) reported Q4 EPS of $4.71, $0.13 worse than the analyst estimate of $4.84. Revenue for the quarter came in at $402.49 million versus the consensus estimate of $371.3 million.
Zymeworks (NASDAQ:ZYME) reported Q4 EPS of $4.71, $0.13 worse than the analyst estimate of $4.84. Revenue for the quarter came in at $402.49 million versus the consensus estimate of $371.3 million.